GeneDx Holdings Corp.

    Jurisdiction
    United States
    ISIN
    US81663L2007 (WGS)
    Sectors
    1. Healthcare
    2. Medical - Healthcare Information Services

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €312.16M
    Gross margin
    67.2%
    EBIT
    €4.68M
    EBIT margin
    1.5%
    Net income
    €1.21M
    Net margin
    0.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €423.94M +35.8% €68.64M +5,566.2%
    €503.62M +18.8% €97.42M +41.9%
    €578.35M +14.8% €132.19M +35.7%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Feeley Kevin CHIEF FINANCIAL OFFICER -378 $125.81 -$47.56K
    Ryan Jason N/A -39K $127.37 -$5.00M
    Casdin Eli N/A -500K $120.90 -$60.45M
    Feeley Kevin CHIEF FINANCIAL OFFICER -388 $105.31 -$40.86K
    Stueland Katherine Chief Executive Officer -2.2K $105.31 -$226.84K

    Earnings Calls

    Latest earnings call: July 29, 2025

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 70K $6.22M -135K Sell

    Add to watchlist

    Notifications